Scientist in a lab working
We transform traditional therapeutics using covalency to imprint and regulate proteins.

Our Mission is to treat diseases with first-and-best-in-class covalent therapeutics for the most significant drug targets by leveraging our cutting-edge capabilities and expertise in chemistry, quantitative proteomics, translational sciences, and deep learning.

Our Science

Nature regulates protein localization, interactions, homeostasis, and function by imprinting post-translational modifications on specific amino acids. Emulating biology, we harness covalency to programmatically imprint and prosecute hard-to-drug targets.

Translational Focus

To translate our discoveries into drugs and maximize our probability of success, we interrogate the imprinting of proteins in their native context at scale, from immortalized cells to more disease-relevant models, such as organoids, primary cells, and biopsies.

Protein Focus

To expand target space and the choice of reactive amino acids, we have developed a proprietary reactome atlas with augmented sequence coverage for thousands of proteins in their native setting. Our state-of-the-art mass spectrometry platform, automation capabilities, and deep learning algorithms are enabling us to illuminate the dark proteome.

Molecular Focus

To advance our programs, we combine our bespoke covalent library, structural proteomics, and computational workflows to imprint amino acid side chains with fragment-like and lead-like molecules bearing both clinically validated and novel reactive warheads.

Our People

Our people are the backbone of what we do. We have an ambitious, strong, creative, and diverse team of experienced scientists and entrepreneurs.

We are consummate team players. We know it takes a village to achieve our goals, and we partner with the best in each field to speed up and maximize our opportunities. We engage key opinion leaders in drug discovery, proteomics, and computational sciences as advisors, consultants, and collaborators.

We are relentless, creative, curious, and seriously spirited. We help each other to thrive while holding ourselves accountable for the work that needs to get done, with the greatest sense of urgency.

Meet Our Leadership

Iván Cornella-Taracido, PhD
Iván Cornella-Taracido, PhD

Chief Scientific Officer & Co-Founder

Plus Sign

Jason Imbriglio, PhD
Jason Imbriglio, PhD

Head of Chemistry and Pharmacology & Co-Founder

Plus Sign

Matt Maisak, PhD
Matt Maisak, PhD

Chief Operating Officer, Roivant Platforms

Plus Sign

Ben Ruprecht, PhD
Ben Ruprecht, PhD

Head of Proteomics Platform & Co-Founder

Plus Sign

We’re always open to new partnerships and collaborations. Let’s work together.